Press Releases Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
7.27 ^USD	-0.68%		-2.81%	+155.99%

Jun. 03	Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing	MT
May. 30	Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Humacyte to Present at the Jefferies Global Healthcare Conference	May. 30	AQ
Humacyte First Quarter 2024 Financial Results and Business Update	May. 13	AQ
Humacyte to Participate at Upcoming Investor Conferences in May	May. 13	AQ
Humacyte First Quarter 2024 Financial Results and Business Update	May. 10	AQ
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024	May. 06	AQ
Humacyte to Host Virtual KOL Event Hemodialysis Access, a Crossroads of Care, on March 28, 2024	Mar. 27	AQ
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024	Mar. 26	AQ
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update	Mar. 25	AQ
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update	Mar. 22	AQ
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024	Mar. 18	AQ
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference	Mar. 04	AQ
Humacyte Announces Proposed Public Offering of Common Stock	Mar. 01	AQ
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference	Mar. 01	AQ
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock	Feb. 29	AQ
Humacyte, Inc. Announces Proposed Public Offering of Common Stock	Feb. 29	AQ
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma	Feb. 09	AQ
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma	Dec. 12	AQ
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference	Nov. 27	AQ
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference	Nov. 24	AQ
Humacyte Announces Two Presentations at the VEITHsymposium of Positive Clinical Results of the Human Acellular Vessel in the Treatment of Vascular Trauma	Nov. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Humacyte, Inc.

Equities

HUMA

US44486Q1031

Press Releases

Filters